1. MILLIPORE CORPORATION AND BIOOUTSOURCE LTD. TO COLLABORATE
Agreement brings together strengths of two global leaders in biosafety testing service industry
BILLERICA, Massachusetts—Millipore Corporation, a leading provider of technologies, tools
and services for the global life science industry, jointly announced with BioOutsource Ltd. that
they have formed a strategic alliance. The industry knowledge, scientific strength and modern
facilities of the two companies combine to offer a world-class biosafety testing partner that
biopharmaceutical manufacturers can rely on as an extension of their own quality assurance
teams. This collaboration will enable Millipore and BioOutsource to bring a full range of
biosafety services to industrial clients who seek a world-class supplier.
The criticality of release testing for vaccine and biological products can create challenges for
biopharmaceutical and pharmaceutical organizations, which, in turn, can lead to delays in
product development and release. Through the combination of Millipore’s state-of-the-art
cGMP facility in Leiden, The Netherlands, and BioOutsource’s custom-built cGMP facility in
Glasgow, U.K., biopharmaceutical manufacturers can feel confident that their drug products
will be produced safely and successfully.
“This alliance offers manufacturers a new alternative for contract testing which will allow them
to deploy their resources in other critical areas. For example, these resources can be re-
focused on drug development or manufacturing and ultimately reduce a product’s time to
market. The complementary nature of both companies’ offerings means customers can
benefit from a best-in-class biosafety portfolio, with technical and scientific strength second to
none,” says Andrew Bulpin, Ph.D., Millipore’s Vice President, Services and Solutions and
Upstream Processing.
“This new joint offering is comprehensive, providing scientific expertise and proven industry
experience. Our goals are to help the industry reduce time spent on the development process
as well as provide a reliable resource for product release testing to specification within a
cGMP environment. This can also lower the necessity of a company maintaining its own
cGMP quality control facility within its organization, thus decreasing overall costs
dramatically,” says Gerry MacKay, Chief Executive Officer, BioOutsource.
About Millipore
Millipore (NYSE: MIL) is a Life Science leader providing cutting-edge technologies, tools, and
services for bioscience research and biopharmaceutical manufacturing. As a strategic
partner, we collaborate with customers to confront the world’s challenging human health
issues. From research to development to production, our scientific expertise and innovative
solutions help customers tackle their most complex problems and achieve their goals.
Millipore Corporation is an S&P 500 company with more than 6000 employees worldwide. For
more information, visit http://www.millipore.com.
ADVANCING LIFE SCIENCE TOGETHER®
Research. Development. Production.

2. About BioOutsource
BioOutsource is a Contract Testing Organisation (CTO) serving the global Biotechnology
Industry. The company provides cGMP testing in areas of biosafety and product
characterization as well as regulatory and consultancy services. The company was formed in
2007 and has quickly established a global customer base with a strong emphasis on
delivering excellent customer service and rapid turnaround times in testing. For more
information, visit
http:www.biooutsource.com
Millipore Media Contact:
Karen Marinella Hall
Director of Corporate Communications
Millipore Corporation
978-715-1567
karen_hall@millipore.com
Investors:
Joshua Young
Director, Investor Relations
978-715-1527
joshua_young@millipore.com
Millipore and ADVANCING LIFE SCIENCE TOGETHER are registered trademarks; the “M”
logo is a trademark of Millipore Corporation.